「ssm」の検索結果

Analyzes malicious Linux ELF (Executable and Linkable Format) binaries including botnets, cryptominers, ransomware, and rootkits targeting Linux servers, containers, and cloud infrastructure. Covers static analysis, dynamic tracing, and reverse engineering of x86_64 and ARM ELF samples. Activates for requests involving Linux malware analysis, ELF binary investigation, Linux server compromise assessment, or container malware analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes encryption algorithms, key management, and file encryption routines used by ransomware families to assess decryption feasibility, identify implementation weaknesses, and support recovery efforts. Covers AES, RSA, ChaCha20, and hybrid encryption schemes. Activates for requests involving ransomware cryptanalysis, encryption analysis, key recovery assessment, or ransomware decryption feasibility.

日本語の概要は準備中です。原文の説明を表示しています。

Strategic clinical trial design feasibility assessment. Analyzes 6 dimensions (endpoint, population, comparator, effect size, duration, regulatory pathway) using precedent trials and FDA guidance. Produces enrollment projections, endpoint recommendations, and approval-pathway analysis. Use for trial-protocol design, power/sample-size estimation, comparator selection, and FDA submission strategy. Driven by precedent-based reasoning rather than first-principles math.

日本語の概要は準備中です。原文の説明を表示しています。

Solve quantitative problems in biophysics — pharmacokinetics (PK volume of distribution, clearance, half-life), epidemiology (R0, attack rate), toxicology (LD50, NOAEL), population genetics (Hardy-Weinberg, Fst), enzyme kinetics (Michaelis-Menten), thermodynamics. Use for first-principles quantitative biology calculations, dose calculations, exposure assessment, and biophysical-property estimation.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluate LLM outputs using frontier models as judges. Use for pairwise model comparison, quality scoring with custom rubrics, and automated evaluation pipelines. Covers position bias mitigation, statistical significance, and generating preference data for DPO/RLHF.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end eDNA metabarcoding from raw amplicons to community ecology. Covers QC, primer removal (mandatory before DADA2 filterAndTrim), denoising with OBITools3 v3 (obi stats plural; DMS-based) or DADA2 ASVs (Callahan 2017), decontam combined method as screening-not-classifier (Davis 2018), tag-jumping with NovaSeq 10x MiSeq caveat (Schnell 2015), Hill-number effective species counts with coverage-based rarefaction (Jost 2006; Chao & Jost 2012; doubling rule), beta-diversity decomposition with MANDATORY PERMANOVA + PERMDISP pair (Anderson & Walsh 2013), constrained ordination, and the read-counts-not-abundance critique (Lamb 2019). Use when processing eDNA samples for biodiversity assessment, deciding ASV vs OTU, configuring OBITools3 v3, interpreting decontam screening, or reporting community comparisons with the dispersion confound check.

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrates an end-to-end CRISPR editing experiment design from target gene to delivery-ready, validatable constructs. Sequences guide design, off-target assessment, edit-modality selection (knockout, base editing, prime editing, HDR knock-in), and template/donor design, with a QC checkpoint at each handoff. Use when designing a complete CRISPR experiment for knockout, point correction, or tagging and the order of operations, the modality decision, and the cross-cutting traps are needed rather than a single step. Defers each step's mechanics to the genome-engineering skills.

日本語の概要は準備中です。原文の説明を表示しています。

Comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling for drug candidates. Integrates ADMET-AI predictions, SwissADME drug-likeness, PubChemTox experimental toxicity, ChEMBL clinical data, Lipinski rule-of-five, and CYP interaction data. Use for drug-likeness assessment, BBB penetration, bioavailability, hepatotoxicity prediction, ADME/PK profiling, or screening compound libraries before lab testing.

日本語の概要は準備中です。原文の説明を表示しています。

Drug and chemical toxicity assessment via adverse outcome pathways (AOPs), real-world FAERS adverse event signals, FDA labels, and toxicogenomic associations. Triangulates molecular initiating event to cellular outcome to organ-level toxicity to clinical adverse event. Use for hepatotoxicity/cardiotoxicity/nephrotoxicity prediction and toxicology reports.

日本語の概要は準備中です。原文の説明を表示しています。

Predicts ADMET properties using ADMETlab 3.0 (119 endpoints with uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES gold-standard endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Multi-method binding pocket detection and druggability assessment. Grid-based, fpocket, and P2Rank detection with druggability scoring, visualization, and cross-structure comparison.

日本語の概要は準備中です。原文の説明を表示しています。

Review Stellar Community Fund (SCF) Build Award applications. Use when evaluating SCF submissions, covering project fit assessment, technical architecture evaluation, team readiness, traction validation, budget analysis, and funding recommendations.

日本語の概要は準備中です。原文の説明を表示しています。

Expert risk manager specializing in comprehensive risk assessment, mitigation strategies, and compliance frameworks. Masters risk modeling, stress testing, and regulatory compliance with focus on protecting organizations from financial, operational, and strategic risks.

日本語の概要は準備中です。原文の説明を表示しています。

Expert security auditor specializing in comprehensive security assessments, compliance validation, and risk management. Masters security frameworks, audit methodologies, and compliance standards with focus on identifying vulnerabilities and ensuring regulatory adherence.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluates and implements age estimation and verification technologies for online services. Covers facial age estimation, digital ID verification, self-declaration with risk assessment, AI-based age estimation, and the accuracy versus privacy tradeoff. Includes ICO guidance and euCONSENT framework. Keywords: age verification, age estimation, facial analysis, digital ID, children, online safety.

日本語の概要は準備中です。原文の説明を表示しています。

Specialized reverse engineering analysis workflows for binary analysis, pattern recognition, and vulnerability assessment

日本語の概要は準備中です。原文の説明を表示しています。

Android Accessibility Service security analysis and pentesting. Use this skill whenever the user mentions Android security testing, accessibility service abuse, RAT detection, malware analysis, ClayRat, PlayPraetor, overlay phishing, credential harvesting, or any Android app security assessment involving AccessibilityService APIs. This skill helps detect malicious accessibility services, analyze abuse patterns, and harden apps against accessibility-based attacks.

日本語の概要は準備中です。原文の説明を表示しています。

Technical research methodology with YAGNI/KISS/DRY principles. Phases: scope definition, information gathering, analysis, synthesis, recommendation. Capabilities: technology evaluation, architecture analysis, best practices research, trade-off assessment, solution design. Actions: research, analyze, evaluate, compare, recommend technical solutions. Keywords: research, technology evaluation, best practices, architecture analysis, trade-offs, scalability, security, maintainability, YAGNI, KISS, DRY, technical analysis, solution design, competitive analysis, feasibility study. Use when: researching technologies, evaluating architectures, analyzing best practices, comparing solutions, assessing technical trade-offs, planning scalable/secure systems.

日本語の概要は準備中です。原文の説明を表示しています。

Detects and removes contamination in genome assemblies via two disjoint workflows - foreign-sequence screening of a single-organism (eukaryote/isolate) assembly with NCBI FCS-GX (GenBank-submission-mandatory), FCS-adaptor, and BlobToolKit blob plots; and MAG/bin quality assessment with CheckM2 plus GUNC (chimerism) plus GTDB-Tk taxonomy, judged against MIMAG. Covers why CheckM2 alone is blind to disjoint-marker chimeras, the FCS-GX RAM wall, organelle/NUMT triage, strain heterogeneity, and the HGT-vs-contamination (tardigrade) trap. Use when screening an assembly for foreign contamination before GenBank submission, assessing MAG completeness/contamination/chimerism, deciding which contigs to remove, or distinguishing real HGT from contaminant contigs.

日本語の概要は準備中です。原文の説明を表示しています。

Handles BED-format genomic intervals (BED3 through BED12, narrowPeak/broadPeak) and the coordinate-system substrate the whole interval category rests on, with bedtools (CLI) and pybedtools/pyranges/pandas (Python). Covers the 0-based half-open vs 1-based-closed convention boundary and the start-1/end-unchanged conversion, the silent failures (chrom-name mismatch, CRLF, lexicographic-vs-version sort under -sorted), genome/chrom.sizes generation, sorting contracts, BED12 block invariants, validation, makewindows, cross-assembly liftover (liftOver/CrossMap), and BED<->VCF/BAM/FASTA conversion. Use when reading, creating, validating, sorting, lifting between genome builds, or converting interval files, preparing inputs for bedtools/tabix/bigBed, or debugging an off-by-one or empty-overlap result.

日本語の概要は準備中です。原文の説明を表示しています。

Transfers gene annotations between genome assemblies via coordinate liftover (UCSC liftOver, CrossMap for same-species version updates) or feature/sequence projection (Liftoff for same/close species, miniprot for protein-level cross-species, TOGA/GeMoMa/CAT for distant clades). Covers the coordinate-vs-projection decision by divergence, why a successful lift is not biological confirmation, reference bias, the silent-dropping of unmapped features, build/PAR/MHC/inversion hazards, and transfer-vs-de-novo validation. Use when annotating a new assembly of a species with an existing reference, harmonizing coordinates across builds, or mapping annotations across related species.

日本語の概要は準備中です。原文の説明を表示しています。

Detect distant homologs using profile and structure-aware methods that go beyond standard BLAST. Use when sequence identity falls into the twilight zone (<35% pairwise), when BLAST fails to find homologs that should exist, when working at metagenomic scale (DIAMOND, MMseqs2), or when structure beats sequence (Foldseek). Covers PSI-BLAST (iterative PSSM), jackhmmer (iterative HMM), HHblits/HHsearch (profile-profile), DIAMOND, MMseqs2, and Foldseek (3Di structural alphabet, van Kempen 2024).

日本語の概要は準備中です。原文の説明を表示しています。

Predicts ADMET properties using ADMETlab 3.0 (119 endpoints with uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES gold-standard endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Core UI/UX engineering skill for building highly interactive, spatial, weightless, and glassmorphism-based web interfaces using GSAP and 3D CSS.

日本語の概要は準備中です。原文の説明を表示しています。